Serum Lactate Dehydrogenase: A Possible Metabolomics Biomarker for the Early Detection of Head and Neck Cancer Lymph Node Metastasis

Pushpa Meena,Anjali Sharma,Dalpat Meena

DOI: https://doi.org/10.52403/ijhsr.20220639

2022-06-24

International Journal of Health Sciences and Research

Abstract:Head and neck cancer (HNC) appears with one of the most recurring sites of cancer, and the percentage of metastases is also high in both localized region and distant areas. Diagnosis of metastases is correlated with poor prognosis, with a median survival of about 10 months. Therefore, early diagnosis is of utmost significance in the treatment of HNC. Metabolomics study targeting altered metabolic pathways exhibits a promising approach for discovering early novel noninvasive targets and biomarkers in HNC lymph node metastasis. An increased level of Lactate dehydrogenase (LDH) has been observed as a major diagnostic metabolomics biomarker for poor survival among HNC patients. It is also recommended as a more efficient biomarker of metastasis. For present study serum samples were collected from healthy controls (n=10) and HNC patients with and without lymph node metastasis (n=10 each). Prepared serum samples were analyzed by UV-spectrophotometer. Further, obtained data were analyzed using the one-way ANOVA test. Significant difference (p<0.05) was reported in the levels of serum metabolites between healthy control group and HNC lymph node metastasis (p<0.0006). Comprehensively, this study provides valuable insights in alteration of serum LDH enzyme level in early diagnosis and prediction of HNC. We proposed LDH could be used as an early metastasis biomarker in screening HNC lymph node metastasis patients. Key words:Head and neck cancer, Lymph node metastasis, Metabolomics, Lactate dehydrogenase (LDH), Serum .